The change in protein function by the amino acid substitution, p.Arg116Gln, was predicted as "Not Tolerated" by SIFT and "Damaging" by PolyPhen. Two other amino acid changes in the same codon were classified previously in our laboratory as pathogenic or likely pathogenic, and reported in the literature in patients with a tuberous sclerosis phenotype (Ali, et al., 2005; Au, et al., 1998; Zhang, et al., 1999) . The contribution of the prediction tools (0.5 point); the other pathogenic changes at this codon (0.5 point), and the published literature (0.5 point) added 1.5 points to the pathogenicity score raising the potential score from 4.0 to 5.5 points. However, with this data alone, the variant pathogenicity score would remain a VUS at a score of 5 (suggesting pathogenic) because minor evidence contribution is capped at the VUS boundary.
Frequency data in the general population: TSC2 c.1832G>A has not been seen in the Exome Sequencing Project (n=6,497 for this nucleotide site) or in our internal normal population study (n=186). In comparison, it was detected in our laboratory in 50 patients (n =7,738) . Using this data we find a statistically significant association between the variant and tuberous sclerosis in patients as compared to controls (P<0.0001). The ethnicity of the patient was unknown. Therefore, we did not know if the correct ethnically-matched control population was used in the analysis. In scoring this variant we would assign +.5 for the positive association result as minor evidence. Minor evidence alone cannot move a score above 5. Therefore, this result did not change the score of the variant.
Co-occurrence:
The TSC2 c.1832G>A has not co-occurred with a known pathogenic or likely pathogenic result in 50 patients with this variant. The binomial test showed that this observation was significant (P=0.002) when compared to an internal 12% TSC2 positive rate for the test. The absence of co-occurrence added 1.0 point. The variant score increased to 6.0 with an interpretation of a likely pathogenic variant.
Variant Segregation Analysis in Families:
No family information was given among the published literature that reported this variant. Segregation analysis was not used on this variant. (Ali, et al., 2005; Au, et al., 1998; Zhang, et al., 1999) .
Functional studies:
Published functional studies demonstrated that TSC2 phosphorylation at two out of three identified phosphorylation sites was prevented by variants at amino acid residue 116 (Nellist, et al., 2005) . The variant expression prevented TSC1 from inhibiting TSC2 ubiquitination (Han, et al., 2008) and regulating downstream mTOR signaling (Nellist, et al., 2008) . These controlled experiments demonstrated that the variant damaged the normal function of the TSC2 protein in the context of its role in the pathophysiology of the disorder. This data adds 1.0 point to bring the total pathogenicity score to 7.0 with a final interpretation of a known pathogenic variant.
Case #2: A benign variant in a patient with maturity-onset of diabetes of the young (MODY)
A variant in the HNF4A gene (MIM# 600281) was identified in a DNA specimen from a patient being evaluated for the possibility of MODY (NM_000457.4;_c.492+6G>A). Below is a step-wise illustration of the five types of data used in assigning a benign score.
Minor Evidence:
The HNF4A gene is a well-known cause MODY with splicing changes published as pathogenic variants. Therefore the minor evidence category was used in scoring. Splicing prediction outcomes were taken into account for the assessment. Five splicing algorithms (see Methods and Materials) were used to evaluate the impact of this variant on the known splice sites and all five algorithms predicted no effect. This resulted in subtracting one point from the midpoint score of 4 to a score of 3 (VUS suggesting benign).
Frequency data in the general population:
The variant was found in the general population at a frequency of 0.11% (Exome Sequencing Project and internal data). The MODY prevalence is 1-9/10,000 (Shields, et al., 2010) . Therefore, the 0.11% frequency was 1.2-fold over the MODY disease allele estimate. This results in the subtraction of one point from the score of 3 above. The resulting score of 2 places the variant in the likely benign classification.
Co-occurrence:
Pathogenic variants co-occurred with this variant in 30% of cases. These were multiple, discrete positive results, not a single pathogenic variant that could be linked in cis in this subset of patients. This observation subtracts one point from the score of 2 above. The resulting score of 1 places the variant in the benign classification.
Variant Segregation Analysis in Families: Not available

Functional studies: Not available
Comments: This case shows that the disease allele frequency threshold may impact variant scoring. For example, we have found, in agreement with published cohort studies, that 4% of all MODY cases are attributed to HN4A pathogenic variants. Therefore, the disease allele frequency was estimated as 0.0036% (4% multiplied by 0.09%). The 0.11% frequency for this variant would then be more than 10-fold above the population disease frequency resulting in subtracting three points. This would place the variant in the benign classification if no additional data suggested that the variant was a risk factor or genetic modifier. Numerous publications show that the relative proportion of MODY cases due to HNF4A mutations varies in different ethnic backgrounds (Al-Daghri, et al., 2014; Bagwell, et al., 2005; Barroso, et al., 2008; Dominguez-Lopez, et al., 2005; Li, et al., 2011; Su, et al., 2014; Taghavi, et al., 2009; Taylor, et al., 2011; Yorifuji, et al., 2012) . It is thus conservative in this case not to use a specific value for attributable risk in calculating the disease allele frequency because the ethnicity of the patient was unknown.
Supp. Figure S1 . Distribution of pathogenicity assessment scores by synonymous (n= 2,846), missense (n= 5,740), intronic (n= 1,107) and in-frame insertions/deletion (n= 246) variant types. Benign variants are scored as 1, 2, or 3 (benign, likely benign, or a VUS-suggesting benign). VUS are variants with a neutral score of 4. Pathogenic are variants with scores of 5, 6, or 7 (VUS-suggesting pathogenic, likely pathogenic, or pathogenic).
Supp. (ii) Synonymous variant predicted to affect a known splice site by 2 algorithms or a non-synonymous variant is predicted to affect a known splice site by 0, 1, or 2 algorithms 0 (iii) Any variant predicted to affect a known splice site by 3, 4, or 5 algorithms +1 (iv) Any variant that predicts a gain of a novel splice site and there is no effect on the known splice site Must have two or more observations of variant from any source in order to use the data.
(i) The variant frequency in the normal population is >10 times higher than the disease allele frequency -3 Must have data from internal or published sources in order to classify.
(ii) The variant frequency in the normal population is between 3 times and 10 times above the disease allele frequency -2 Can be from public database, published or internal data; if from ESP must have 10 or more occurrences of a variant to use.
(iii) The variant frequency is equal to or up to 3 times higher than the disease allele frequency -1 Note if the disease prevalence not well established, use the most conservative estimate.
A. Association testing in patient vs. the control frequency data (i) The variant is enriched in clinically characterized patients as compared to controls.
+1 Must be statistically significant using chi square test; only use when variant has been seen 6 or more times in clinically documented patients, and with no ethnic bias.
(ii) The variant is enriched in clinically uncharacterized internal patients +.5 Must be statistically significant using the chi square test; uncharacterized internal patients are treated as minor evidence (ii) The variant appears to associate with the disease phenotype in genotyped family members +1 Must have marginal statistical significance (0.05<P<0.1). Treat as minor evidence.
Functional studies
(i) The variant is damaging to protein function +1 Must be relevant to the molecular basis of disease.
(ii) The variant has no impact on protein function -1 Must be relevant to the molecular basis of disease, and a complete analysis of all functions of a protein that are relevant to the disease.
A. Structural impact (iii) Frameshift, nonsense, and canonical splice site variants associated with well-characterized disease phenotypes that will lead to nonsense-mediated decay +2 Loss of function disease model must be demonstrated in literature or through multiple documented observations of null/truncating variants occurring across the entirety of gene in patients. Demonstration of expected phenotype occurring with the variant (evidence 1D), as well as the variant's absence (dominant genes) from a large multi-ethnic control population or appropriately low frequency in a general population will add +1 point and lead to classification of the variant to pathogenic.
(iv) Nucleotide change is different, but results in the same amino acid change of a variant previously scored as pathogenic.
+2 This line of evidence may be used if splicing predictions do not show a difference in splicing profiles between the two variants. Demonstration of expected phenotype occurring with the variant (evidence 1D) as well as the variant's absence (dominant genes) from a large multi-ethnic control population or appropriately low frequency in a general population will add +1 point and lead to classification of the variant to pathogenic. Exceptions to the type of evidence: Gene-specific exceptions (e.g. cysteine changes in NOTCH3) to these rules were applied in circumstances where the disease mechanism or molecular biology was well characterized. c All calculations started from a score of 4 (midpoint VUS) and points were added or subtracted based on the type of evidence, outcome and rules. If the final score resulted in a number between two whole numbers, the score was rounded towards the conservative midpoint value. A variant's score was capped at 2 (likely benign) under the following conditions to safeguard against the limitations of public databases: 1 Published experimental data supporting the splice-site prediction.
